Sihuan Company Profile

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. has achieved sound development in the past years and has grown into the leading pharmaceutical company in China’s prescription drug market. The Group has been the largest cardio-cerebral vascular drug franchise in China’s prescription drug market since 2007. The success of the Group can be attributed to its unique and proven sales & marketing model, extensive nationwide distribution network, diversified portfolio of market-leading drugs, and strong research & development capabilities.

Diversified Product Portfolio

The company’s current product portfolio is mainly dominated by exclusive and proprietary products which encompass the top five medical therapeutic areas in China: cardio-cerebral vascular system, central nervous system, metabolism, oncology and anti-infectives. Our major products such as Kelinao, Anjieli, Chuanqing, Qu’Ao GM1 and Oudimei are very widely used in the treatment of various cardio-cerebral vascular diseases.

Unique and proven sales and market model

Our successful sales and marketing model is unique and is underpinned by an extensive network of over 3,000 distributors covering close to 10,000 hospitals and medical institutions across China. Managed and supported by our in-house dedicated sales and product managers, who ensure the efficiency, productivity and stability of our distribution network, our unique sales model has proven to be highly successful and cost-efficient resulting in rapid and deep market penetration.

Strong research and development

Our strengths in research and development provide us with an edge in developing new drugs and first-to-market generic drugs. Our R&D team, one of the largest in China’s pharmaceutical industry,comprisesover 400 personnel, and focuses on developing innovative drugs and first-to-market generic drugs that meet market demand. Our investment on R&D has been well above the domestic average and accounted for about 6% to 10% of sales since 2007. Currently, we have over 80 new drugs under various development stages, including 14 innovative patented drugs. We have applied for 600 patents including 34 PCTs, and over 300 patents were granted. Several of our innovative products were awarded as significant innovative drug projects by local and national governments.

Development strategy

Taking advantage of China's growing economy and ongoing healthcare reforms, we will actively seek to secure long-term growth opportunities for the Company by taking steps to expand our marketing and distribution network, enhance research and development capabilities, and optimize production capacity. We will also continually expand and enhance our portfolio of products by making use of our proven multiple channel strategy that includes acquisition and cooperation with overseas pharmaceutical companies.

 

Our mission is to be an international leader with fully integrated capabilities in R&D, production and sales and marketing. We will continue to be dedicated to the development and marketing of cardio-cerebral vascular drugs and to provide the best pharmaceutical products to patients.

Top